Therabron Therapeutics Announces New Study Aimed at the Creation of Multiple Novel Isoforms of the Company's Lead Product Candidate

Data Presented at the 2016 Biology of Acute Respiratory Tract Infection Conference

Mar 02, 2016, 09:37 ET from Therabron Therapeutics, Inc.

ROCKVILLE, Md., March 2, 2016 /PRNewswire/ -- Therabron Therapeutics, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory care, today announced presentation of data unveiling the creation of a program aimed at developing multiple novel isoforms of the Company's lead product candidate, recombinant human CC10 protein (rhCC10). The study entitled "Modification of CC10 Protein by Reactive Oxygen Species (ROS) during Acute Lung Injury" was presented at the 2016 Biology of Acute Respiratory Tract Infection Conference in Galveston, TX.

Clara (club) cell 10kDa protein (CC10) is expressed by respiratory epithelial cells and plays an important protective role in healthy lungs by inhibiting multiple inflammatory pathways. Studies have shown that excessive inflammation in respiratory disease leads to important modifications of the native CC10 protein.  These recently reported insights have enabled Therabron to develop new rhCC10 isoforms ex-vivo through simulation of chemical reactions that occur in respiratory inflammatory conditions in-vivo.

"These observations enhance the potentially transformative impact that rhCC10-based therapeutics could have in the future. In addition to our lead, hospital-focused phase 2 program, we are pursuing development initiatives focused on ambulatory respiratory disease with confirmed deficiency in native CC10, including COPD," said Dr. Thomas F. Miller, President and Chief Executive Officer of Therabron. "We have created a number of isoforms of rhCC10 with the goal of evaluating their application in chronic respiratory disease and we are actively pursuing a series of exclusivities to protect these newly discovered molecules."

Therabron's lead rhCC10 protein product candidate (CG100), is delivered by intratracheal instillation to preterm infants in a phase 2 clinical trial with the objective of reducing chronic respiratory morbidities following hospital discharge.

About Therabron Therapeutics, Inc.

At Therabron Therapeutics, we are advancing a platform of novel therapeutic proteins in an effort to change how a variety of neglected and under-treated respiratory and fibrotic conditions are managed.  We are a privately held, clinical-stage, biopharmaceutical company, developing a new class of drugs based on the naturally occurring secretoglobin family of proteins which includes the CC10 protein -- a molecule with both anti-inflammatory and immunomodulatory mechanisms.  Therabron's product candidates have the potential to become first-in-class, biologic therapeutics.  For additional information, please visit www.therabron.com


SOURCE Therabron Therapeutics, Inc.



RELATED LINKS

http://www.therabron.com